What happened with VYGR today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Voyager Therapeutics is working on treatments for diseases such as Alzheimer’s, Parkinson’s and Friedreich’s ataxia, both independently and with partners. A central part of its research is getting treatments across the blood-brain barrier. Its TRACER platform discovers virus shells designed to carry gene therapies into the brain after intravenous administration, while Voyager NeuroShuttle uses receptor-binding molecules to carry treatments across that barrier without a virus.
Pharmaceutical partners pay Voyager for access to its technology and programs and reimburse agreed research and development costs. Voyager also receives payments when partnered programs reach specified milestones. Neurocrine supplies most of its collaboration revenue, with Novartis another important source; Alexion also licenses its technology. These agreements can provide royalties if resulting products reach commercial sales.
Voyager has no product-sales revenue and no approved product in any jurisdiction. Its anti-tau antibody candidate VY7523 is in early clinical trials, while its other active candidates remain preclinical. Future milestone and royalty income depends on development results, regulatory approvals and partners continuing to fund and advance programs; partners can deprioritize programs or terminate agreements.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Beyond this list, Voyager also depends on Alexion to develop licensed TRACER-based CNS gene therapies and on Transition Bio to discover TDP-43 small molecules.
Voyager relies on Neurocrine Biosciences to license its genetic medicines and pay development costs, milestones and potential royalties for partnered Parkinson’s and Friedreich’s ataxia treatments. The two Neurocrine agreements generated $34.0 million of Voyager’s $40.4 million collaboration revenue in 2025, making progress in these programs particularly important to watch.
Novartis pays Voyager to use its gene-delivery shells, or capsids, and collaborates on spinal muscular atrophy and Huntington’s disease treatments that could bring Voyager milestone payments and sales royalties. Watch those programs separately from the 2022 license agreement: two terminated programs under that agreement stopped carrying milestone or royalty eligibility on February 1, 2026.
Denali Therapeutics competes with Voyager in carrying medicines across the blood-brain barrier and developing brain-directed tau treatments for Alzheimer’s disease. Watch the brain distribution and sustained gene suppression reported for Denali’s antibody and oligonucleotide delivery platforms alongside Voyager’s NeuroShuttle results.
Ionis Pharmaceuticals challenges Voyager’s Alzheimer’s tau-silencing gene therapy with a Biogen-partnered medicine that targets genetic messages, an antisense therapy. Results from that tau program provide a competing test of lowering tau rather than of Voyager’s gene-delivery technology.
Prothena’s tau antibody partnered with Bristol Myers Squibb competes with Voyager’s anti-tau antibody for Alzheimer’s disease; both companies also pursue TDP-43 neurodegeneration programs. Watch the Alzheimer’s program BMS-986446 for the antibody rivalry, while Prothena’s TDP-43 CYTOPE program addresses ALS.
Biogen competes with Voyager’s tau-silencing gene therapy through its Ionis-partnered antisense program, while its marketed SKYCLARYS treats Friedreich’s ataxia, which Voyager and Neurocrine also target. Watch tau-program results for the Alzheimer’s rivalry and SKYCLARYS news for the existing Friedreich’s ataxia treatment market.
Lexeo Therapeutics’ LX2006 competes with Voyager and Neurocrine’s program in developing gene therapies for Friedreich’s ataxia. LX2006’s focus on the disease’s cardiac manifestations makes its development news a specific part of that rivalry to watch.
Solid Biosciences’ SGT-212 competes with Voyager and Neurocrine’s gene therapy for Friedreich’s ataxia. Follow SGT-212 development rather than product sales: Solid’s supplied disclosures describe investigational or preclinical programs, not sales-generating products.
Sarepta Therapeutics’ ELEVIDYS liver-safety restrictions inform the safety and regulatory environment for Voyager’s intravenously delivered TRACER gene therapies, rather than a direct treatment rivalry. In November 2025, Sarepta announced a boxed warning for acute liver injury and acute liver failure and removed non-ambulatory patients from ELEVIDYS’ U.S. indication.
Larimar Therapeutics’ nomlabofusp offers a competing non-gene-therapy approach to the Friedreich’s ataxia market targeted by Voyager and Neurocrine. Nomlabofusp’s clinical development is the relevant signal: Larimar had no commercialized product or revenue from any source through the filing period.
Design Therapeutics competes with Voyager and Neurocrine’s Friedreich’s ataxia gene therapy by developing an approach that changes FXN gene expression. Watch development of that approach, not sales: Design had no approved products or product-sale revenue as of December 31, 2025.
Gain Therapeutics’ GT-02287 targets GCase dysfunction in Parkinson’s disease with a small molecule, competing with Voyager and Neurocrine’s GBA1 gene therapy. Gain had completed Phase 1 testing and was preparing to start Phase 2 in the third quarter of 2026, making GT-02287’s clinical progress the news to watch.
uniQure competes with Voyager in CNS genetic medicines through overlapping Huntington’s disease programs targeting MSH3 and competing ALS development efforts. Watch the MSH3 programs as preclinical work, rather than as approved Huntington’s disease treatments.
Alector’s brain-penetrant tau-silencing and GCase programs pursue the Alzheimer’s and Parkinson’s opportunities targeted by Voyager’s tau programs and Neurocrine-partnered GBA1 gene therapy. Its tau-targeting siRNA and GCase enzyme-replacement work are preclinical or research programs, so their development news—not marketed-product results—is the relevant comparison.
Fed Interest Rate Decision
Voyager’s cash and marketable securities earn interest that helps fund its research and development, so the Fed’s benchmark rate matters because it influences the interest income supporting its operations.
Expected4.0%Last release4.0%
If it comes in above expectations
If the Fed’s rate is above expectations, higher borrowing costs could make any debt Voyager takes on more expensive, while higher interest income on its cash and securities could partly support its funding runway.
If it comes in below expectations
If the Fed’s rate is below expectations, lower borrowing costs could make any debt Voyager takes on cheaper, but reduced interest income on its cash and securities could weaken support for funding research and development.
Neurocrine Biosciences Inc earningsNBIX
Neurocrine Biosciences’ report can show whether it is still advancing its partnered programs with Voyager and bearing part of their development costs.
Look for updates on the partnered Friedreich’s ataxia and GBA1 Parkinson’s programs, and for any disclosed development spending or progress. Continued work and cost support would mean Voyager is not carrying the full development burden alone. A pause or reduced support would mean Voyager may have to spend more itself or slow development.
Solid Biosciences Inc. earningsSLDB
Solid Biosciences’ report can show how its Friedreich’s ataxia gene therapy is progressing, revealing the same-disease competition facing Voyager and Neurocrine.
Look for concrete development progress and clinical evidence for SGT-212. Progress with supporting evidence would put a more advanced rival gene therapy against Voyager and Neurocrine’s program; delays or limited evidence would mean less pressure from this competitor, not proof that Voyager’s treatment works.
Ionis Pharmaceuticals, Inc. earningsIONS
Ionis Pharmaceuticals’ report can show progress in its Biogen-partnered tau-lowering treatment, a competing approach to Voyager’s tau-silencing program.
Look for clinical progress and evidence that Ionis and Biogen’s antisense medicine—a treatment that targets genetic messages—can lower tau. Stronger progress would give Voyager’s tau-silencing program a better-supported competing approach; delays or limited evidence would weaken that rival’s case, but would not show that Voyager’s treatment works.
Denali Therapeutics Inc. earningsDNLI
Denali Therapeutics’ report can show how its brain-delivery platforms and tau programs are progressing, setting a competitive benchmark for Voyager’s own delivery work.
Watch whether Denali’s delivery technology gets medicines into the brain and whether tau suppression lasts. Stronger evidence on both would raise the benchmark for Voyager’s NeuroShuttle brain-delivery platform; limited distribution or short-lived suppression would show that competitors have not yet solved the same challenge.
Prothena Corporation plc earningsPRTA
Prothena’s report can show progress in its Bristol Myers Squibb-partnered anti-tau antibody, a competitor to Voyager’s VY7523 for Alzheimer’s disease.
Look at clinical progress and evidence for BMS-986446 alongside Voyager’s VY7523, an anti-tau antibody in early-stage trials. Stronger progress by Prothena and Bristol Myers Squibb would make the competition more immediate for VY7523; delays or limited evidence would leave the rival less advanced, but would not prove VY7523 works.
Voyager Therapeutics, Inc. earningsThis company
Voyager relies on collaboration revenue to support research, and this report shows how that revenue compares with the cash its operations use.
Read collaboration revenue alongside cash used in operating activities. Higher collaboration revenue with less operating cash use would show partners are helping shoulder more of the research burden and easing cash pressure. Lower revenue with greater cash use would mean Voyager has to rely more on its own funds or find other financing.
Gain Therapeutics, Inc. earningsGANX
Gain Therapeutics’ report can show progress in its GCase-targeting small molecule, an alternative to the GBA1 Parkinson’s gene therapy from Voyager and Neurocrine Biosciences.
Watch whether GT-02287 advances through clinical testing and whether the evidence supports this small-molecule approach. Clearer progress would give patients and clinicians another potential option competing with GBA1 gene therapy; delays or limited evidence would leave that alternative less developed, not show that Voyager’s program works.
